Entries by Thomas Gabrielczyk

MGI turns a new page in the human genome era with ultra-high throughout DNBSEQ-T7 sequencer*

Amidst the rapid evolution of DNA sequencing technologies in past years, the industry has been working tirelessly to make genomics more accessible. Since the Human Genome Project, which saw scientists from six countries coming together to map the first human genome at nearly $3 billion over 13 years, the cost of whole-genome sequencing has fallen to less than $1,000 today. Yet, the quest to produce larger amounts of short- and long-read data in a shorter span of time and at an even lower cost continues.

Anti-ID antibody production

An anti-idiotypic anti­body (anti-ID Ab) can recognise and bind to the idiotypic center of another antibody. Anti-idiotype antibodies are widely used in therapeutic drug development, such as immunogenicity assessments, pharmacokinetic/pharmacodynamics (PK/PD) studies, and vaccine development.

Avantium gets EU grant

Avantium NV will get a €3m EU funding for a feasibility study of the electrochemical conversion of CO2 to consumer products.

Evotec and BMS intensify R&D on protein degraders

Hamburg-headquartered Evotec SE has extended and expanded its three-year-old partnership with Bristol Myers Squibb in targeted protein degradation ("molecular glue degraders") for an additional eight years. 

The small molecule degraders link an E3 ubiquitin ligase with the molecular target, mostly in cancer and autoimmunity indications. The interaction results in ubiquitination and subsequent degradation of the recruited protein and is hoped to provide a ong-lasting therapeutic effect.
Bristol Myers Squibb brings in a huge library of E3 ligase modulators. Under the terms of the agreement, both parties will leverage all of Evotec’s appropriate platforms as well as AI/ML-based drug discovery.
Under the new agreement, Evotec cashes in an upfront payment of $200m and is eglible to obtain up to $5bn in milestone payments and tiered royalties on product sales.